Fat-soluble vitamins as disease modulators in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 127, Issue S196, 2013, Pages 16-23

  Torkildsen, O ^a,b   Loken Amsrud K I ^c,d   Wergeland, S ^a,b   Myhr, K M ^a,b   Holmoy T ^d,e  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c INNLANDET HOSPITAL TRUST   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Multiple sclerosis; Nutrition; Treatment; vitamins

Indexed keywords

4 [3,5 BIS (TRIMETHYLSILYL)BENZAMIDO] BENZOIC ACID; ALPHA TOCOPHEROL; BETA INTERFERON; CALCITRIOL; COLECALCIFEROL; EBSELEN; INTERLEUKIN 1BETA; MENAQUINONE; PHYTOMENADIONE; PLACEBO; PREDNISOLONE; RETINOIC ACID; RETINOID DERIVATIVE; RETINOL; TAMIBAROTENE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP; FAT; VITAMIN;

ALLERGIC ENCEPHALITIS; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; EXPERIMENTAL STUDY; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OBSERVATIONAL STUDY; OSTEOPOROSIS; PEROXIDATION; SYSTEMATIC REVIEW; THERAPY EFFECT; VITAMIN SUPPLEMENTATION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; MEDLINE; OBSERVATION; STATISTICS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FATS; HUMANS; MEDLINE; MULTIPLE SCLEROSIS; OBSERVATION; PUBMED; VITAMIN A; VITAMIN D; VITAMIN E; VITAMIN K; VITAMINS;

EID: 84877102755     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12045     Document Type: Article

References (63)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Pugliatti M, Harbo HF, Holmøy T et al. Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008;188:34-40.
3. SWANK RL. Treatment of multiple sclerosis with low-fat diet: result of seven years' experience. Ann Intern Med 1956;45:812-24. No abstract available.
4. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
5. Simon KC, Munger KL, Ascherio A. XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented? J Neurol Sci 2011;311:1-8.
6. Chang H. Retinoic acid, immunity, and inflammation. Vitam Horm 2011;86:83-101.
7. Ross AC, Chen Q, Ma Y. Vitamin A and retinoic acid in the regulation of B-cell development and antibody production. Vitam Horm 2011;86:103-26.
8. Farso MC, Krantic S, Rubio M, Sarfati M, Quirion R. The retinoid, 6-[3-adamantyl-4 hydroxyphenyl]-2-napthalene carboxylic acid, controls proliferative, morphological, and inflammatory responses involved in microglial activation without cytotoxic effects. Neuroscience 2011;192:172-84.
9. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008;8:685-98.
10. Massacesi L, Abbamondi AL, Giorgi C, Sarlo F, Lolli F, Amaducci L. Suppression of experimental allergic encephalomyelitis by retinoic acid. J Neurol Sci 1987;80:55-64.
11. Massacesi L, Abbamondi AL, Sarlo F, Amaducci L. The control of experimental allergic encephalomyelitis with retinoic acid. Further studies Riv Neurol 1987;57:166-9.
12. Massacesi L, Castigli E, Vergelli M et al. Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. J Clin Invest 1991;88:1331-7.
13. Racke MK, Burnett D, Pak SH et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 1995;1:154.
14. Wang T, Niwa S, Bouda K et al. The effect of Am-80, one of retinoids derivatives on experimental allergic encephalomyelitis in rats. Life Sci 2000;67:1869-79.
15. Klemann C, Raveney BJ, Klemann AK et al. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am J Pathol 2009;174:2234-45.
16. Miyagawa N, Homma T, Kagechika H, Shudo K, Nagai H. Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. Pharmacology 2003;67:21-31.
17. Zhang SM, Hernán MA, Olek MJ, Spiegelman D, Willett WC, Ascherio A. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 2001;57:75-80.
18. Royal W III, Gartner S, Gajewski CD. Retinol measurements and retinoid receptor gene expression in patients with multiple sclerosis. Mult Scler 2002;8:452-8.
19. Besler HT, Comoǧlu S, Okçu Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neuro Sci 2002;5:215-20.
20. Løken-Amsrud KI, Myhr KM, Bakke SJ et al. Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Mult Scler 2012; PMID: 22907941 (epub Aug 20).
21. Qu ZX, Dayal A, Jensen MA, Arnason BG. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis. Arch Neurol 1998;55:315-21.
22. Holick MF. The vitamin D epidemic and its health consequences. J Nutr 2005;135:2739S-48S.
23. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
24. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
25. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67:373-8.
26. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1, 25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374:334-8.
27. Boonstra A, Barrat FJ, Crain C et al. 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001;167:4974-80.
28. Smolders J, Thewissen M, Peelen E et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS ONE 2009;4:e6635.
29. Eyles DW, Smith S, Kinobe R et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.
30. Overbergh L, Decallonne B, Valckx D et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 2000;120:139-46.
31. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86:888-94.
32. Holmøy T, Lossius A, Gundersen TE et al. Intrathecal levels of vitamin D and IgG in multiple sclerosis. Acta Neurol Scand 2012;125:e28-31.
33. Lemire JM, Archer DC. A1, 25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
34. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861-4.
35. Spach KM, Nashold FE, Dittel BN et al. IL-10 signaling is essential for 1, 25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006;177:6030-7.
36. Wergeland S, Torkildsen O, Myhr KM et al. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS ONE 2011;6:e26262.
37. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008;7:268-77.
38. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-5.
39. Munger KL, Levin LI, Hollis BW et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8.
40. van der Mei IA, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007;254:581-90.
41. Soilu-Hanninen M, Airas L, Mononen I et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005;11:266-71.
42. Soilu-Hanninen M, Laaksonen M, Laitinen I et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008;79:152-7.
43. Simpson S Jr, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
44. Mowry EM, Krupp LB, Milazzo M et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618-24.
45. Løken-Amsrud KI, Holmøy T, Bakke SJ et al. Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology 2012;17:79:267-73.
46. Kimball SM, Ursell MR, O'Connor P et al. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007;86:645-51.
47. Smolders J, Peelen E, Thewissen M et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS ONE 2010;5:e15235.
48. Burton JM, Kimball S, Vieth R et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010;74:1852-9.
49. Soilu-Hanninen M, Aivo J, Lindstrom BM et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565-71.
50. Kampman MT, Steffensen LH, Mellgren SI et al. Effect of vitamin D3 supplementation on relapses, disease progression and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012;18:1144-51.
51. Stein MS, Liu Y, Gray OM et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77:1611-8.
52. Lassmann H, van HJ. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 2011;585:3715-23.
53. Pekmezci D. Vitamin E and Immunity. Vitam Horm 2011;86:179-215.
54. Heppner FL, Roth K, Nitsch R, Hailer NP. Vitamin E induces ramification and downregulation of adhesion molecules in cultured microglial cells. Glia 1998;22:180-8.
55. Mazzanti CM, Spanevello R, Ahmed M et al. Pre-treatment with ebselen and vitamin E modulate acetylcholinesterase activity: interaction with demyelinating agents. Int J Dev Neurosci 2009;27:73-80.
56. Goudarzvand M, Javan M, Mirnajafi-Zadeh J, Mozafari S, Tiraihi T. Vitamins E and D3 attenuate demyelination and potentiate remyelination processes of hippocampal formation of rats following local injection of ethidium bromide. Cell Mol Neurobiol 2010;30:289-99.
57. Jiménez-Jiménez FJ, de Bustos F, Molina JA et al. Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. Neurosci Lett 1998;249:65-7.
58. Salemi G, Gueli M, Vitale F et al. Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 2010;9:19-21.
59. Karg E, Klivényi P, Németh I, Bencsik K, Pintér S, Vécsei L. Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 1999;246:533-9.
60. Karg E, Klivenyi P, Bencsik K, Turi S, Vecsei L. Alpha-tocopherol and NADPH in the erythrocytes and plasma of multiple sclerosis patients. Effect of interferon-beta-1b treatment. Eur Neurol 2003;50:215-9.
61. Li J, Lin JC, Wang H et al. Novel role of vitamin k in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci 2003;23:5816-26.
62. Moriya M, Nakatsuji Y, Okuno T, Hamasaki T, Sawada M, Sakoda S. Vitamin K2 ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 2005;170:11-20.
63. Smolders J, Hupperts R, Barkhof F et al. Efficacy of vitamin D as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011;311:44-9.